Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.

ABSTRACT:

Background

Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may be worth exploring in patients who do not benefit from their first TPO-RA. We investigated the outcomes of switching from rh-TPO to eltrombopag or vice versa in immune thrombocytopenia (ITP) patients.

Methods

This prospective, open-label, observational investigation included 96 adult ITP patients who needed to switch between rh-TPO and eltrombopag between January 2020 and January 2021 at Peking University People's Hospital in China. The study evaluated response rates and platelet counts at different time points after the switch

SUBMITTER: Cai X 

PROVIDER: S-EPMC9771238 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature